These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 3553166)

  • 21. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
    Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.
    Paulino Ramirez Diaz S; Gil Gregório P; Manuel Ribera Casado J; Reynish E; Jean Ousset P; Vellas B; Salmon E
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):744-8. PubMed ID: 16035121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Very low-dose neuroleptic treatment in two patients with agitation associated with Alzheimer's disease.
    Risse SC; Lampe TH; Cubberley L
    J Clin Psychiatry; 1987 May; 48(5):207-8. PubMed ID: 2883174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study.
    Engelborghs S; Maertens K; Nagels G; Vloeberghs E; Mariën P; Symons A; Ketels V; Estercam S; Somers N; De Deyn PP
    Int J Geriatr Psychiatry; 2005 Nov; 20(11):1028-37. PubMed ID: 16250064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT; Pejović V; Miller ML; Graham SM
    Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measuring treatment response in Alzheimer's disease clinical trials.
    Caban-Holt A; Bottiggi K; Schmitt FA
    Geriatrics; 2005 Jun; Suppl():3-8. PubMed ID: 16025769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical rating scale for symptoms of psychosis in Alzheimer's disease.
    Reisberg B; Ferris SH
    Psychopharmacol Bull; 1985; 21(1):101-4. PubMed ID: 3983330
    [No Abstract]   [Full Text] [Related]  

  • 28. Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease.
    Cahn-Weiner DA; Grace J; Ott BR; Fernandez HH; Friedman JH
    Neuropsychiatry Neuropsychol Behav Neurol; 2002 Jun; 15(2):79-87. PubMed ID: 12050470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease.
    Raskind MA
    J Clin Psychiatry; 1998; 59 Suppl 9():28-32. PubMed ID: 9720484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Childhood conduct problems, stages of Alzheimer's disease, and physical aggression against caregivers.
    O'Leary D; Jyringi D; Sedler M
    Int J Geriatr Psychiatry; 2005 May; 20(5):401-5. PubMed ID: 15852459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of behavioral and affective symptoms in Alzheimer's disease.
    Patterson MB; Schnell AH; Martin RJ; Mendez MF; Smyth KA; Whitehouse PJ
    J Geriatr Psychiatry Neurol; 1990; 3(1):21-30. PubMed ID: 2346584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 'Residence is not home' is a particular type of delusion associated with cognitive decline of Alzheimer's disease.
    Nakatsuka M; Meguro K; Nakamura K; Akanuma K; Yamaguchi S
    Dement Geriatr Cogn Disord; 2014; 38(1-2):46-54. PubMed ID: 24556941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale.
    Auer SR; Monteiro IM; Reisberg B
    Int Psychogeriatr; 1996; 8(2):247-66. PubMed ID: 8994895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sleep in Alzheimer's disease and the sundown syndrome.
    Vitiello MV; Bliwise DL; Prinz PN
    Neurology; 1992 Jul; 42(7 Suppl 6):83-93; discussion 93-4. PubMed ID: 1630644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Behavioral profile of Alzheimer's disease in Chinese elderly--a validation study of the Chinese version of the Alzheimer's disease behavioral pathology rating scale.
    Lam LC; Tang WK; Leung V; Chiu HF
    Int J Geriatr Psychiatry; 2001 Apr; 16(4):368-73. PubMed ID: 11333423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study.
    Canevelli M; Adali N; Cantet C; Andrieu S; Bruno G; Cesari M; Vellas B;
    J Neurol; 2013 Jul; 260(7):1859-65. PubMed ID: 23504051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical variables associated with psychosis in Alzheimer's disease.
    Kotrla KJ; Chacko RC; Harper RG; Doody R
    Am J Psychiatry; 1995 Sep; 152(9):1377-9. PubMed ID: 7653698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sundowning and circadian rhythms in Alzheimer's disease.
    Volicer L; Harper DG; Manning BC; Goldstein R; Satlin A
    Am J Psychiatry; 2001 May; 158(5):704-11. PubMed ID: 11329390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remediable behavioral symptomatology in Alzheimer's disease.
    Reisberg B; Borenstein J; Franssen E; Shulman E; Steinberg G; Ferris SH
    Hosp Community Psychiatry; 1986 Dec; 37(12):1199-201. PubMed ID: 3804220
    [No Abstract]   [Full Text] [Related]  

  • 40. S-adenosyl-L-methionine in the treatment of Alzheimer's disease.
    Cohen BM; Satlin A; Zubenko GS
    J Clin Psychopharmacol; 1988 Feb; 8(1):43-7. PubMed ID: 3350998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.